3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
7
Gastrointestinal
4
Thoracic
2
Plasma cell
1
Lymphoid
1
Gynecologic
1
CNS
1
Conditions
Lung Neoplasms
2
Venous Thromboembolism
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
510
Cisplatin
410
Pemetrexed
400
Radiotherapy
285
Docetaxel
244
Paclitaxel
228
pembrolizumab
226
Gemcitabine
198
Drug Therapy
191
Bevacizumab
190
Erlotinib Hydrochloride
189
Radiosurgery
177
Nivolumab
168
durvalumab
155
Etoposide
155
osimertinib
126
atezolizumab
109
Gefitinib
96
Blood Specimen Collection
93
Magnetic Resonance Spectroscopy
91
Vinorelbine
90
anlotinib
89
Surgical Procedures, Operative
85
Ipilimumab
62
Immunotherapy
62
Surveys and Questionnaires
60
sintilimab
59
Specimen Handling
59
tislelizumab
58
Irinotecan
57
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Tinzaparin
×
Thoracic
×
Clear all
NCT03090880
2022-11-17
PROVE
Assistance Publique - Hôpitaux de Paris
Phase 3
Terminated
59 enrolled
NCT00475098
2016-09-02
TILT
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
553 enrolled